DCTH
Price:
$11.34
Market Cap:
$362.58M
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphal...[Read more]
Industry
Medical - Specialties
IPO Date
2018-05-03
Stock Exchange
NASDAQ
Ticker
DCTH
According to Delcath Systems, Inc.’s latest financial reports and current stock price. The company's current ROE is -316.26%. This represents a change of 179.49% compared to the average of -113.16% of the last 4 quarters.
The mean historical ROE of Delcath Systems, Inc. over the last ten years is -534.06%. The current -316.26% ROE has changed -40.78% with respect to the historical average. Over the past ten years (40 quarters), DCTH's ROE was at its highest in in the June 2023 quarter at 2.98%. The ROE was at its lowest in in the December 2017 quarter at -2838.35%.
Average
-534.06%
Median
-103.35%
Minimum
-6654.42%
Maximum
1.21%
Discovering the peaks and valleys of Delcath Systems, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 101.86%
Maximum Annual ROE = 1.21%
Minimum Annual Increase = -805.50%
Minimum Annual ROE = -6654.42%
Year | ROE | Change |
---|---|---|
2023 | -302.20% | -145.21% |
2022 | 668.42% | -398.58% |
2021 | -223.87% | 101.86% |
2020 | -110.90% | -151.74% |
2019 | 214.36% | 66.60% |
2018 | 128.67% | -101.93% |
2017 | -6654.42% | -651.73% |
2016 | 1.21% | -805.50% |
2015 | -170.96% | 78.47% |
2014 | -95.79% | -4.92% |
The current ROE of Delcath Systems, Inc. (DCTH) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
47.45%
5-year avg
49.16%
10-year avg
-534.06%
Delcath Systems, Inc.’s ROE is greater than NeuroPace, Inc. (-205.41%), greater than Surmodics, Inc. (-9.56%), less than ProSomnus, Inc. (50.75%), greater than CVRx, Inc. (-89.06%), less than LivaNova PLC (1.88%), less than Electromed, Inc. (15.32%), greater than OrthoPediatrics Corp. (-7.64%), greater than TELA Bio, Inc. (-556.18%), less than TransMedics Group, Inc. (18.74%), greater than Telesis Bio, Inc. (-280.28%), greater than AVITA Medical, Inc. (-28.99%), greater than ClearPoint Neuro, Inc. (-62.10%), greater than Sight Sciences, Inc. (-47.28%), greater than Treace Medical Concepts, Inc. (-51.12%), greater than Pulmonx Corporation (-53.88%), less than IRadimed Corporation (23.98%), greater than Orthofix Medical Inc. (-21.25%), less than Integer Holdings Corporation (7.30%),
Company | ROE | Market cap |
---|---|---|
-205.41% | $332.51M | |
-9.56% | $567.19M | |
50.75% | $8.18M | |
-89.06% | $313.00M | |
1.88% | $2.54B | |
15.32% | $250.27M | |
-7.64% | $546.67M | |
-556.18% | $112.65M | |
18.74% | $2.14B | |
-280.28% | $674.82K | |
-28.99% | $338.47M | |
-62.10% | $433.22M | |
-47.28% | $180.18M | |
-51.12% | $434.21M | |
-53.88% | $243.25M | |
23.98% | $687.03M | |
-21.25% | $662.63M | |
7.30% | $4.52B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Delcath Systems, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Delcath Systems, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Delcath Systems, Inc.'s ROE?
How is the ROE calculated for Delcath Systems, Inc. (DCTH)?
What is the highest ROE for Delcath Systems, Inc. (DCTH)?
What is the 3-year average ROE for Delcath Systems, Inc. (DCTH)?
What is the 5-year average ROE for Delcath Systems, Inc. (DCTH)?
How does the current ROE for Delcath Systems, Inc. (DCTH) compare to its historical average?